Recombinant Human CD40 /TNFRSF5 Protein, His Tag, 200µg

Background
CD40 is also known as TNFRSF5, Bp50, CDW40, MGC9013, TNFRSF5 and p50, is a member of the TNF receptor superfamily which are single transmembrane-spanning glycoproteins, and plays an essential role in mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. CD40 is a costimulatory protein found on antigen presenting cells and is required for their activation. The binding of CD154 (CD40L) on TH cells to CD40 activates antigen presenting cells and induces a variety of downstream effects. CD40 contains 4 cysteine-rich repeats in the extracellular domain, and is expressed in B cells, dendritic cells, macrophages, endothelial cells, and several tumor cell lines. The extracellular domain has the cysteinerich repeat regions, which are characteristic for many of the receptors of the TNF superfamily. Interaction of CD40 with its ligand, CD40L, leads to aggregation of CD40 molecules,which in turn interact with cytoplasmic components to initiate signaling pathways. Early studies on the CD40-CD40L system revealed its role in humoral immunity. Defects in CD40 result in hyper-IgM immunodeficiency type 3 (HIGM3), an autosomal recessive disorder characterized by an inability of B cells to undergo isotype switching, as well as an inability to mount an antibody-specific immune response, and a lack of germinal center formation.

Source
Recombinant Human CD40, His Tag (CD0-H5228) is expressed from human 293 cells (HEK293). It contains AA Glu 21 - Arg 193 (Accession # P25942-1).
Predicted N-terminus: Glu 21

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 21.1 kDa. The protein migrates as 29-32 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.
 
Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Cancer immunotherapy via synergistic coactivation of myeloid receptors CD40 and Dectin-1"
Wattenberg, Coho, Herrera et al
Sci Immunol (2023) 8 (89), eadj5097
(2) "CD40/CD40L expression and its prognostic value in cervical cancer"
Grazia, Bastos, Villa
Braz J Med Biol Res (2023) 56, e13047
(3) "Hub genes and their key effects on prognosis of Burkitt lymphoma"
Xu, Wang, Zhang et al
World J Clin Oncol (2023) 14 (10), 357-372
Showing 1-3 of 16806 papers.

Citations

(1) "Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist"
Authors: Upadhyaya P, Lahdenranta J, Hurov K, et al.
Journal: Journal for immunotherapy of cancer 2021
Application: SPR
(2) "ANTI-CD40 ANTIBODY, ANTIGEN BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF"
Authors: Yan Shude , et al
Journal: US20200148778A1 2020
Application: ELISA